NCT01995058Phase 2Terminated

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Study sponsor: Exelixis

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2014-11Actual

Enrollment · participants54Actual

Source updated2026-01-08Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-01-08 · 1 field changed

Primary outcomes · main study measures

Text edit · unverified significance

− Previous value

measure: Radiographic progression free survival (PFS)

+ Updated value

measure: Radiographic Progression Free Survival (PFS)

The saved outcome text may be shortened. Check the source for full wording.

Check registry source

Study details

Conditions studied

Prostate Cancer; Castration Resistant Prostate Cancer; Prostatic Neoplasms

Treatments or interventions studied

cabozantinibDrugAlso known as XL184
abirateroneDrugAlso known as Zytiga(R), abiraterone acetate
prednisoneDrug

Primary outcomes · main study measures

measure: Radiographic Progression Free Survival (PFS); description: PFS is defined as the time from randomization to the earlier of disease progression or death due to any cause, as assessed by Independent Radiology Committee (IRC). The sponsor terminated the study early due to business reasons. As such, no data were collected for efficacy analyses.; timeFrame: Up to 18 Months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history